Ngenla Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis rates of growth hormone deficiency, established use of daily somatropin therapies, advancements in recombinant dna technology, increasing pediatric endocrinology awareness, expansion of specialty hormone clinics.

The growth in the forecast period can be attributed to rising demand for long-acting endocrine therapies, increasing adult ghd diagnosis rates, growing focus on quality-of-life outcomes, expansion of biologics manufacturing capacity, stronger payer support for innovative hormone treatments. Major trends in the forecast period include increasing adoption of long-acting growth hormone therapies, rising preference for reduced injection frequency treatments, growing focus on patient adherence improvement, expansion of recombinant hormone manufacturing capabilities, enhanced emphasis on personalized endocrine care.

The increasing prevalence of pediatric growth hormone deficiency (GHD) is expected to drive the growth of the Ngenla market. Pediatric GHD is a condition in which the body fails to secrete enough growth hormone, affecting children's physical development and overall health. The rising prevalence of GHD is attributed to better awareness, improved diagnostic capabilities, and greater access to healthcare services. Ngenla, a long-acting recombinant human growth hormone (somatrogon), addresses this by providing a sustained release of growth hormone through once-weekly injections. This reduces the treatment burden of daily injections, improves adherence, and promotes growth in children with GHD. For example, in January 2024, the National Library of Medicine (NLM) estimated that GHD affects 1 in 3,500 to 1 in 10,000 children, depending on diagnostic criteria and testing methods. As the prevalence of pediatric GHD increases, Ngenla’s market is expected to grow.

A key trend in the Ngenla market is the focus on long-acting growth hormone therapies that improve treatment adherence and overall outcomes for both pediatric and adult patients with GHD. These therapies, designed for sustained hormone release, reduce injection frequency and enhance patient compliance. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received FDA approval for Ngenla, a once-weekly growth hormone analog for treating pediatric patients aged three years and older with growth failure due to insufficient endogenous growth hormone secretion.

In July 2024, OPKO Health entered a partnership with HealthCare Royalty (HCRx) through non-dilutive note purchase agreements, backed by OPKO’s profit share payments from Pfizer related to Ngenla. This agreement allows OPKO to retain a substantial portion of the profit shares in the short term while potentially benefiting in the long term.

Major companies operating in the ngenla market are Pfizer Inc.

North America was the largest region in the ngenla market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngenla market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ngenla market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the ngenla market by increasing costs of imported biologic raw materials, cell culture media, single-use bioprocessing systems, cold-chain logistics components, and specialized packaging used in long-acting hormone production. North America and Europe are most affected due to dependence on cross-border biologics supply chains, while Asia-Pacific faces higher costs for manufacturing inputs and distribution infrastructure. These tariffs are contributing to elevated production expenses and pricing pressures for specialty endocrine therapies. However, they are also encouraging localized biologics manufacturing, regional fill-finish investments, and strengthened domestic supply chains for long-term hormone therapy production.

The ngenla market research report is one of a series of new reports that provides ngenla market statistics, including ngenla industry global market size, regional shares, competitors with a ngenla market share, detailed ngenla market segments, market trends and opportunities, and any further data you may need to thrive in the ngenla industry. This ngenla market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ngenla is a long-acting human growth hormone (somatrogon) developed to treat growth hormone deficiency (GHD) in both children and adults. It works by replacing the natural growth hormone in individuals with insufficient production, promoting growth and managing growth-related disorders.

The main indications for Ngenla include growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and small for gestational age (SGA). Growth hormone deficiency is a condition where the body fails to produce enough growth hormone, resulting in poor growth in children and adults. Ngenla is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by different patient groups, including pediatric and adult patients.

The ngenla market consists of sales of prefilled injection pens and somatrogon solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.